Materialise did not grow in the first quarter of 2026. Yet the company may have delivered something more important: better margins, positive free cash flow, stronger net cash and a more focused portfolio.
The quarter highlights a different kind of additive-manufacturing thesis. Materialise is not trying to win through aggressive hardware volume or acquisition-led scale. It is attempting to improve the quality of a diversified business built around medical applications, software and manufacturing services.
Addithive verdict
Thesis status: Improving in quality, still lacking growth acceleration.
Materialise is showing stronger cost control, cash generation and portfolio discipline. The next proof point is whether Medical and Software can sustain profitable growth while Manufacturing stabilizes.
What changed?
- Q1 2026 revenue was stable at €66.3 million.
- Gross margin increased to 57.2%, from 55.3% a year earlier.
- Adjusted EBIT rose to €2.47 million, from €0.65 million.
- Adjusted EBITDA increased to €8.05 million, from €6.15 million.
- Net profit reached €1.82 million, versus a €0.54 million loss.
- Operating cash flow was €6.91 million and free cash flow was positive.
- Net cash increased to €72.8 million.
- Medical revenue grew 6.7%, while Manufacturing revenue declined 8.1%.
- Materialise transferred its eyewear business to management after selling Rapidfit.
Flat revenue can still hide a better quarter
Total revenue was almost unchanged year over year, but the income statement improved materially. Gross profit rose despite flat sales, adjusted EBIT nearly quadrupled and all three operating segments improved adjusted EBITDA.
This suggests that the company is getting more disciplined about pricing, mix and operating cost. Research, sales and administrative expenses remained broadly stable in aggregate, allowing gross-margin gains to flow through to profit.
The improvement is more credible because it also appeared in cash flow. Materialise generated positive operating and free cash flow while increasing net cash and buying back shares.
Medical remains the economic engine
Materialise Medical generated €33.2 million of revenue, up 6.7%, and €9.2 million of adjusted EBITDA. The segment represented roughly half of group revenue but substantially more than half of segment EBITDA.
This matters because medical additive manufacturing is built around patient-specific workflows, regulated software, clinical relationships and repeatable procedure volumes. Those characteristics can create stronger switching costs and more resilient economics than general-purpose printing services.
The risk is that Medical’s adjusted EBITDA margin slipped to 27.8% from 29.1%. Growth remains healthy, but investors should watch whether future investment or pricing pressure limits margin expansion.
Software is showing operating leverage
Software revenue declined 1.4%, yet segment adjusted EBITDA rose 87% and margin improved to 11.6% from 6.1%.
That is encouraging because software should ultimately be one of Materialise’s most scalable assets. The company’s long-term value depends not only on selling licenses, but on embedding its workflow, build-preparation and quality tools inside industrial production systems.
The next step is top-line acceleration. Margin improvement without revenue growth can support earnings for a period, but durable software value requires rising adoption and recurring revenue.
Manufacturing is still the weak point
Manufacturing revenue fell 8.1% to €23.5 million. Segment adjusted EBITDA improved from a loss to a small positive result, but the 1.2% margin remains thin.
The segment is exposed to customer project timing, industrial cyclicality and price competition. It also carries a more capital- and labor-intensive cost structure than software.
The encouraging signal is that management restored positive segment EBITDA despite lower revenue. The stronger signal would be revenue stabilization accompanied by a sustained mid-single-digit or better margin.
Exiting eyewear and Rapidfit sharpens the portfolio
Materialise sold Rapidfit at the end of March and then agreed to transfer its eyewear activities to the eyewear management team. Materialise will retain a minority stake in the new eyewear company, while the financial terms were not disclosed.
These actions indicate that management is willing to remove businesses that consume capital or attention without strengthening the core platform. The company expects an impairment charge related to eyewear in Q2, so the exit is not costless.
Strategically, however, the direction is clear: concentrate resources on Medical, Software and selected Manufacturing capabilities where Materialise has stronger differentiation.
The balance sheet is becoming an advantage
Materialise ended Q1 with €133.0 million of cash, €60.1 million of gross debt and €72.8 million of net cash. The company also continued its share-buyback program.
That financial position distinguishes Materialise from many pure-play AM peers that rely on recurring equity issuance. It gives the company flexibility to invest in software, medical growth and selective strategic opportunities without immediate financing pressure.
Still, buybacks create value only if the business compounds earnings and cash flow. They should not substitute for organic growth.
What would prove the thesis?
- Medical sustains mid- to high-single-digit growth with stable margins.
- Software returns to growth while maintaining double-digit adjusted EBITDA margins.
- Manufacturing revenue stabilizes and margin rises meaningfully above breakeven.
- Adjusted EBIT reaches the €10 million to €12 million 2026 guidance range.
- Free cash flow remains positive over multiple quarters.
- Portfolio exits reduce complexity without weakening customer relationships.
- Net cash continues to rise after investment and buybacks.
- Management demonstrates that capital allocation improves per-share value.
What would break the thesis?
- Medical growth slows materially or margins continue to compress.
- Software remains stagnant despite cost improvements.
- Manufacturing stays structurally low margin.
- Eyewear and other exits generate larger-than-expected impairment or restructuring costs.
- Free cash flow improvement proves temporary.
- Share buybacks consume cash without improving earnings power.
- Full-year revenue or adjusted EBIT guidance is reduced.
Research conclusion
Materialise’s first-quarter results did not show a growth breakout. They showed something rarer in the public additive-manufacturing universe: operating discipline, positive free cash flow and a strong net-cash position.
The company is also narrowing its portfolio around areas where it has deeper technical and commercial advantages.
The thesis is therefore improving in quality rather than speed. Materialise now needs to prove that better margins and portfolio focus can support renewed top-line growth.
Research use only. This article is not investment advice.
Read the full Materialise investor profile →